FDA Grants Breakthrough Therapy Status to Olomorasib for Lung Cancer
INDIANAPOLIS, Sept. 4, 2025 – The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib,...
KRAS G12C mutation
Advertisement
NATCO Launches Generic Bosentan Tablets for Oral Suspension in the U.S. with 180-Day Exclusivity
Hyderabad, India, August 20, 2025 – NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) today announced the launch of...
SmartLabs and Sonrai Form Exclusive AI Partnership to Accelerate Precision Medicine and Scientific Discovery
SmartLabs and Sonrai Analytics today announced a global strategic alliance to integrate Sonrai’s next-generation AI platform, Sonrai Discovery, into...
Stramsen Biotech Submits Pre-IND Package to FDA for SBX1977, Seeks Phase 2 Pathway in Wound Care
Stramsen Biotech Inc., a plant-based biotechnology company, has announced the submission of its Pre-Investigational New Drug (Pre-IND) package to...
D3 Bio Wins FDA Breakthrough and Orphan Drug Designations for D3S-001 in KRAS G12C-Mutated Cancers
Shanghai – August 28, 2025 — D3 Bio, Inc., a clinical-stage precision oncology company, announced that the U.S. Food...
Advertisement
